Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271965 | 0.92 | MARS1 (0.72) | MARS1SLC2A1 | |
| SCHEMBL12406475 | 0.92 | MARS1 (0.72) | MARS1SLC2A1 | |
| SCHEMBL2173453 | 0.92 | MARS1 (0.72) | MARS1SLC2A1 | |
| Hydrochloric Acid SCHEMBL2173823 | 0.91 | MARS1 (0.71) | MARS1SLC2A1 | |
| Hydrochloric Acid SCHEMBL2173612 | 0.91 | MARS1 (0.71) | MARS1SLC2A1 | |
| Hydrochloric Acid SCHEMBL2173635 | 0.91 | MARS1 (0.71) | MARS1SLC2A1 | |
| SCHEMBL11904767 | 0.91 | MARS1 (0.61) | MARS1SLC2A1 | |
| SCHEMBL12370237 | 0.88 | MARS1 (0.58) | MARS1SLC2A1 | |
| SCHEMBL2272871 | 0.88 | MARS1 (0.61) | MARS1SLC2A1 | |
| SCHEMBL2275781 | 0.85 | MARS1 (0.61) | MARS1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000756-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-4259115-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Crestone, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116867484-A | Methods and compounds for treating autism spectrum disorders | 克莱斯通公司 | 2023-10-10 | — | — | CN | claimed |
| WO-2022125691-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-2094714-B1 | SUBSTITUTED THIENOPYRIDONE COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE INC (US) | 2012-08-15 | — | — | EP | claimed |
| US-7994192-B2 | 5-[3-(6,8-Dibromo-1,2,3,4-tetrahydro-quinolin-4-ylamino)-propylamino]-4H-thieno [3,2-b]pyridin-7-one, used as inhibitors of bacterial methionyl tRNA synthetase, administered for the treatment of bacterial infections; therapy for Clostridium difficile based infections | CRESTONE, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2094714-A2 | SUBSTITUTED THIENOPYRIDONE COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Crestone, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| US-20090163536-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION | REPLIDYNE, INC. (US) | 2009-06-25 | — | — | US | claimed |
| US-20080146609-A1 | Substituted Thienopyridone Compounds With Antibacterial Activity | REPLIDYNE, INC. (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008039639-A2 | SUBSTITUTED THIENOPYRIDONE COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2008039642-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION | REPLIDYNE, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20240000756-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4259115-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Crestone, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116867484-A | Methods and compounds for treating autism spectrum disorders | 克莱斯通公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022125691-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20080146609-A1 | Substituted Thienopyridone Compounds With Antibacterial Activity | REPLIDYNE, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146609-A1 | Substituted Thienopyridone Compounds With Antibacterial Activity | REPLIDYNE, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008039639-A2 | SUBSTITUTED THIENOPYRIDONE COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039639-A2 | SUBSTITUTED THIENOPYRIDONE COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | CRESTONE, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039642-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION | REPLIDYNE, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146609-A1 | Substituted Thienopyridone Compounds With Antibacterial Activity | TRDMT1, TYMS, WARS1 | MARS1 9/4885SLC2A1 4553/4885 |
| US-20240000756-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | MTR, GARS1, AANAT | MARS1 82/4885SLC2A1 3875/4885 |
| US-20090163536-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION | MTR, GARS1, CPS1 | MARS1 31/4885SLC2A1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.